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A biosensor for L-glutamic acid (Glu), constructed by
immobilisation of L-glutamate oxidase onto lipid-coated 60
mm radius Pt wire with poly(o-phenylenediamine), was
used amperometrically in attempts to detect glutamate in
brain extracellular fluid (ECF) in the awake, freely
moving rat at 1 s intervals. An implanted carbon paste
electrode served to monitor simultaneous changes in brain
ascorbate (AA). There were spontaneous, parallel changes
in both signals, depending on the behavioural state of the
animal, giving rise to a significant positive correlation
coefficient between the two variables. The application of a
mild stressor (10 s tail pinch) caused an immediate
increase in both signals. The effects of inhibiting energy
metabolism, together with an existing hypothesis linking
Glu and AA in the ECF, were used to conclude that AA
does not interfere electrochemically with the biosensor in
vivo, that there are parallel changes in extracellular Glu
and AA concentrations under normal physiological
conditions, and that sub-micromolar physiologically
related changes in brain Glu could be detected in the ECF
several days after implantation of the electrodes.
l-Glutamate (Glu) in brain extracellular fluid (ECF) has been
the focus of much analytical interest recently with the
development of a variety of new approaches to its detection and
quantification.1–6 The fascination with brain Glu is well
justified; this amino acid is the most widespread intercellular
chemical messenger (neurotransmitter) within the mammalian
central nervous system, playing a major role in a wide range of
brain functions, and has been implicated in a number of brain
disorders.7
Many of these new techniques rely on the use of permselec-
tive dialysis membranes, either to collect perfusate,5 convey
perfusate to an on-line analyser4,6 or to house a sensing
electrode.1,3 While time resolutions of the order of 1 min have
been reported for dialysis-based techniques,4,6 either the need to
collect a minimum volume for analysis, dead volume in the flow
system or the diffusion of analyte to the internal sensing
electrode limits the time resolution of these approaches.
We recently reported the development of a sensitive and
selective amperometric biosensor based on glutamate oxidase
(GluOx) immobilised onto Pt wire with electrosynthesised non-
conducting polymer and designed for detection of Glu directly
in brain ECF.8 The problem of interference by endogenous
electroactive reducing agents, especially ascorbic acid (AA),
was resolved by electrosynthesising poly(o-phenylenediamine)
(PPD) onto a lipid layer containing adsorbed enzyme. Although
these Pt/PPD/GluOx sensors showed excellent sensitivity and
selectivity in vitro,8 it remained to be seen whether they would
have sufficient sensitivity, selectivity and stability in vivo to
detect brain Glu. We report here preliminary data that suggest
that Pt/PPD/GluOx electrodes are able to monitor small (sub-
micromolar) physiologically-induced changes in ECF Glu
levels at 1 s intervals, even several days after sensor im-
plantation.
Materials and methods
Reagents and solutions
The enzyme l-glutamate oxidase (GluOx from Streptomyces
sp. X-119-6, EC 1.4.3.11, 200 U ml21 in 20 mmol l21
potassium phosphate buffer, pH 7.4) was obtained as a generous
gift from Yamasa, Chiba, Japan and stored at 220 °C. The lipid
phosphatidylethanolamine (PEA, type II-S) and bovine serum
albumin (BSA, fraction V) were obtained from Sigma Chemical
(St. Louis, MO, USA). All chemicals, including o-phenyl-
enediamine (PD, Sigma), l-glutamic acid (Glu, Sigma) and l-
ascorbic acid (AA, Aldrich, Milwaukee, WI, USA), were used
as supplied.
Solutions of PD monomer (300 mmol l21) were made up in
10 ml of a phosphate-buffered saline solution (PBS). Stock
solutions of 100 mmol l21 Glu and AA were prepared in doubly
distilled water and 0.01 mol l21 HCl, respectively. Experiments
in vitro were carried out in PBS (pH 7.4) that consisted of 0.15
mol l21 NaCl (Merck, Poole, UK), 0.04 mol l21 NaH2PO4
(Merck) and 0.04 mol l21 NaOH (Merck). Solutions were kept
refrigerated at 4 °C when not in use.
Instrumentation and software
Experiments were microcomputer controlled with in-house
software as described before.9 Although raw data was sampled
at 1000 Hz, the program, as constructed at present for on-line
screen plots over several hours, was constrained to a time
resolution of 1 s for recorded data. The linear and non-linear
regression analyses were performed using the graphical soft-
ware package Prism (GraphPad Software, San Diego, CA,
USA). Calibration experiments were carried out using a
standard three-electrode set-up with a saturated calomel
electrode (SCE) as the reference and a silver wire in a glass
sheath as the auxiliary electrode.
Preparation of the working electrodes
The biosensors, based on Pt cylinders (60 mm radius), were
prepared as described recently8 by cutting strips of Teflon-
coated platinum wire, sliding the Teflon along the wire to
expose about 1 mm of metal. The exposed metal was coated
with PEA (to enhance AA blocking properties) before being dip
coated with GluOx. The enzyme-coated wire was introduced
into PBS containing the monomer (300 mmol l21 PD) and 5
mg ml21 of the non-enzyme protein BSA,10 and electro-
polymerisation carried out at 0.7 V vs. SCE for 15 min.
Calibrations were performed amperometrically at 0.7 V vs.
SCE in quiescent PBS for Glu (0–10 mmol l21) and AA (0–1
mmol l21) before implantation of the electrodes. Calibrations of
the biosensor after several days of implantation were not
possible because of disruption of the polymer–enzyme coating
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upon removal from the tissue; in vitro and in vivo data indicate,
however, that neither lipids,9 proteins11 nor prolonged exposure
to brain tissue9,12 have an appreciable effect on PPD/enzyme-
based electrodes.
Carbon paste electrodes (CPEs) for the detection of AA were
made from Teflon-coated silver wire (125 mm internal diameter,
160 mm external diameter, Clark Electromedical Instruments,
Reading, UK) as described previously.9
Electrode implantation
Either one Pt/PPD/GluOx sensor and one CPE, or two CPEs,
were implanted bilaterally in the striatum of male Sprague
Dawley rats (about 250 g initial weight) as described in detail
previously.9,12 The co-ordinates, with the head level between
bregma and lambda, were AP 1.0, L 2.5 (from bregma) and DV
5.4 (from skull) for the Pt/PPD/GluOx sensor and DV 4.8 for
CPEs. Silver wires (200 mm) placed in the cortex served as
reference and auxiliary electrodes. The animals were placed in
their individual recording environments immediately after
surgery and allowed to recover overnight before recording
commenced. Amperometric data were recorded simultaneously
with the CPE at 250 mV (peak potential for AA in vivo9) and
with the Glu biosensor at 700 mV continuously over several
days.
Results and discussion
The signals recorded from the Glu biosensor and CPE in
striatum of the awake, freely moving rat showed spontaneous
changes that were correlated with behaviour: when the rat was
displaying activities, such as locomotion, grooming or feeding,
both signals increased relative to the resting state. There are two
possible explanations for the high correlation: both electrodes
detect AA in vivo; or the biosensor detects Glu, but there are
parallel changes in Glu and AA concentrations in the ECF as
predicted by the Glu–AA heteroexchange hypothesis.13 This
model suggests that, when Glu is taken up from the ECF into a
cell (after its release from neurones, for example), AA is
released into the ECF by an energy-dependent carrier-mediated
exchange of Glu and AA.13
Energy (glucose) metabolism was therefore disrupted by the
administration of insulin to distinguish between these two
possibilities. In rats implanted with two CPEs to detect striatal
AA bilaterally, insulin caused a parallel decrease in the
electrochemical AA signal on the two sides of the brain. In other
experiments involving one Glu sensor and one CPE in each
striatum, insulin caused opposite changes in the two signals (see
Table 1). The effects of insulin are consistent with a breakdown
in the Glu uptake system and indicate that the parallel changes
in the biosensor and AA signals observed under normal
physiological conditions are not due to electrochemical inter-
ference by AA with the biosensor, but to parallel changes in the
concentration of the two neurochemicals in the ECF.13
Although AA is the main interferent in brain ECF, where its
concentration is about 500 mmol l21, there are other possible
sources of interference such as dopamine (DA) and its
metabolite DOPAC.14 Because this is a ‘first generation’
biosensor detecting H2O2, changes in pO2 might also be
expected to affect the sensor, although recent studies in vitro15
and in vivo12 have indicated that PPD/enzyme sensors are
insensitive to oxygen over the physiological range of concen-
trations. The results from a pilot study (Table 1) on a range of
drugs that affect both Glu and possible interference substances
in the ECF suggest that the biosensor detects Glu without
contamination by interference under these conditions.
To determine the response time of the biosensor in vivo, we
used a mild stressor: a 10 s tail pinch applied with a forceps.
Fig. 1 shows the time course at 1 s intervals for both the
biosensor and AA signals. There was an immediate increase in
the biosensor signal that reached a plateau by 3 s; this
corresponded to an estimated change in extracellular Glu of
about 0.5 mmol l21. There was a spike when the forceps was
removed, followed by a fast decrease. The changes in the AA
signal recorded with the contralateral CPE were in the same
direction, although slightly more sluggish than the changes
detected with the biosensor.
We suggest that Fig. 1 provides additional evidence (see
Table 1) that the biosensor detected ECF Glu and was not
affected by AA. The residual response of the biosensor to AA in
vitro is very small (80 nA cm22 mmol21 l) and slow with a t95%
of about 1 min.8 The finding, therefore, that the biosensor signal
changed more rapidly in response to tail pinch than the AA
signal (recorded with the CPE) indicates that the changes
recorded with the biosensor are unlikely to be due to AA.
Furthermore, we reported that the response time for Glu at the
biosensor was less than the mixing time (about 10 s) in the batch
analysis set-up in vitro.8 The data in Fig. 1 suggest that the
inherent response time to substrate is of the order of 1 s as
reported for other PPD-based biosensors in vitro.16
Conclusions
The preliminary results reported here suggest that Pt/PPD/
GluOx biosensors are sensitive, selective and stable enough to
detect physiologically induced sub-micromolar changes in the
concentration of Glu in brain ECF at 1 s time resolution several
days after sensor implantation, despite changes in extracellular
Table 1 Qualitative effects of systemic administration of a number of
pharmacological agents on the signal recorded in rat striatum with a Pt/PPD/
GluOx sensor and literature effects on both extracellular glutamate and
possible interference compounds found in the ECF
Pt/PPD/GluOx Effect on Interferent
Drug signal ECF glutamate effect
Insulin Ñ Ñ20 AA —*
(15 U kg21 i.p.)
Apomorphine Ñ Ñ21 DOPAC —22
(2 mg kg21 i.p.) DA —22
Chloral hydrate — —† DOPAC Ñ23
(400 mg kg21 i.p.) DA Ñ23
O2Ñ25
* Present results. † Data not available for chloral hydrate, but several
studies suggest that other general anaesthetics decrease Glu in brain
ECF.19,24
Fig. 1 Example of amperometric responses, recorded at 1 s intervals with
a Pt/PPD/GluOx biosensor (Glu) and CPE (AA) placed bilaterally in rat
striatum, 6 days after implantation. The period of application of a mild
stressor (10 s tail pinch) is indicated by the black box. Corresponding
changes in ECF Glu and AA are predicted in the Glu–AA heteroexchange
model.13
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AA concentration. This represents significant progress in the
development and application of glutamate biosensors in brain
systems. Reports of such applications are rare and have tended
to be on acutely implanted (a few hours) electrodes in
anaesthetised preparations where non-physiological stimula-
tion, such as elevated K+ or electrical stimulation, led to large
changes in extracellular Glu.17
Further interference experiments, similar to the ones re-
ported, need to be carried out with a wider range of drugs and
analysed quantitatively to substantiate our conclusions. It also
remains to be seen whether sub-second resolution can be
achieved by reconfiguring the software, and whether ECF Glu
originates from synaptic neurotransmitter release or from a
metabolic pool of amino acids.18,19
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